Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis
- PMID: 18674476
- DOI: 10.4065/83.8.917
Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis
Abstract
Objective: To determine the value of positron emission tomography (PET) in diagnosing occult malignancies in patients with paraneoplastic neurologic syndromes (PNSs) at Mayo Clinic's site in Rochester, MN.
Patients and methods: We retrospectively reviewed the medical charts of all 107 patients who underwent PET from January 1, 2000, to July 31, 2006, for the indication of suspected PNS. Three patients did not meet inclusion criteria. PET results were considered positive if increased fludeoxyglucose F 18 uptake indicated malignancy (24 patients). Results from computed tomography were interpreted as positive if any suspect lesion was consistent with malignancy (26 patients).
Results: One hundred four patients with PNS were identified from the PET central database; 73 patients had at least 1 positive result for paraneoplastic antibody, and 31 had antibody-negative PNS. Malignancy was confirmed pathologically in 10 patients, of whom 8 had positive PET results. There were 2 cases of confirmed malignancy (fallopian tube adenocarcinoma and spindle cell uterine carcinoma) for which PET results were negative. Two patients with positive PET results declined biopsy. Computed tomography was able to identify 3 of the 10 malignancies detected. Five cases of malignancy were detected only by PET. All patients with confirmed malignancy had positive results for at least 1 paraneoplastic antibody. One patient with positive results for PNS antibody and negative PET results was diagnosed as having small cell carcinoma on a follow-up PET scan after 27 months. PET had sensitivity, specificity, positive predictive value, and negative predictive value of 80%, 67%, 53%, and 88%, respectively.
Conclusion: PET scan was shown to be more sensitive than computed tomography for detecting occult malignancy (confirmed by positive test results for autoantibody) among patients with suspected PNS. The greatest clinical utility of PET could be in its high negative predictive value.
Similar articles
-
Accuracy of FDG-PET/CT and paraneoplastic antibodies in diagnosing cancer in paraneoplastic neurological syndromes.Rev Esp Med Nucl Imagen Mol. 2016 Jan-Feb;35(1):17-21. doi: 10.1016/j.remn.2015.07.001. Epub 2015 Aug 8. Rev Esp Med Nucl Imagen Mol. 2016. PMID: 26260889
-
FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.Brain. 2004 Oct;127(Pt 10):2331-8. doi: 10.1093/brain/awh247. Epub 2004 Sep 10. Brain. 2004. PMID: 15361417
-
18 F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or indeterminate conventional imaging: a retrospective analysis of the Ontario PET Access Program, with systematic review and meta-analysis.Curr Oncol. 2019 Aug;26(4):e458-e465. doi: 10.3747/co.26.4583. Epub 2019 Aug 1. Curr Oncol. 2019. PMID: 31548813 Free PMC article.
-
[(18)F-FDG PET/CT in the evaluation of patients suspected of paraneoplastic neurological syndrome].Rev Esp Med Nucl Imagen Mol. 2015 Jul-Aug;34(4):236-43. doi: 10.1016/j.remn.2015.02.006. Epub 2015 Apr 10. Rev Esp Med Nucl Imagen Mol. 2015. PMID: 25864422 Spanish.
-
Paraneoplastic neurological syndromes and the role of PET imaging.Oncology. 2010;78(2):150-6. doi: 10.1159/000312657. Epub 2010 Apr 13. Oncology. 2010. PMID: 20389137 Review.
Cited by
-
Paraneoplastic Neurological Syndromes: Transitioning Between the Old and the New.Curr Oncol Rep. 2022 Oct;24(10):1237-1249. doi: 10.1007/s11912-022-01279-z. Epub 2022 Apr 27. Curr Oncol Rep. 2022. PMID: 35476177 Review.
-
Carcinoma of unknown primary and paraneoplastic dermatomyositis.World J Clin Oncol. 2015 Dec 10;6(6):295-8. doi: 10.5306/wjco.v6.i6.295. World J Clin Oncol. 2015. PMID: 26677443 Free PMC article. Review.
-
18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis.Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1575-1587. doi: 10.1007/s00259-017-3722-4. Epub 2017 May 27. Eur J Nucl Med Mol Imaging. 2017. PMID: 28550611
-
Detection of underlying malignancy in patients with paraneoplastic neurological syndromes: comparison of 18F-FDG PET/CT and contrast-enhanced CT.Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1014-24. doi: 10.1007/s00259-013-2372-4. Epub 2013 Mar 16. Eur J Nucl Med Mol Imaging. 2013. PMID: 23503574
-
Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.Antibodies (Basel). 2023 Jul 31;12(3):50. doi: 10.3390/antib12030050. Antibodies (Basel). 2023. PMID: 37606434 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources